Overview

Join our distinguished faculty as they discuss recognizing, diagnosing, and managing polyneuropathy caused by hereditary transthyretin-mediated (hATTR) amyloidosis.  They will provide an overview of hATTR amyloidosis and review the clinical profile of AMVUTTRA^® (vutrisiran) a treatment for the polyneuropathy of hATTR amyloidosis in adults.  AMVUTTRA has warnings and precautions for reduced serum vitamin A levels and recommended supplementation.  The most common adverse reactions are arthralgia, dyspnea, and vitamin A decreased.  For additional information about AMVUTTRA, please see the Important Safety Information and full Prescribing information at www.amvuttrahcp.com.

Disclaimers

The content in this Industry Expert Theater  was created independently by the sponsor.  The views and/or opinions do not necessarily reflect the views of HFSA or its members.  The activity "Discover AMVUTTRA^® (vutrisiran) (no CEUs)" is not sponsored or endorsed by the HFSA.  The Industry Expert Theater is not offered in the HFSA-accredited continuing education catalog; therefore, it is ineligible for continuing education units.  No committee members or representatives of the HFSA has been involved in the planning of this activity.